Alma vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health network connecting clients to in-network therapists; handles credentialing, billing, and insurance contracting for affiliated clinicians; one of largest US therapist networks.
About
Alma is a New York-based mental health company that operates a network of therapists and psychiatrists, providing them with the business infrastructure to run private practices while accepting insurance. Alma handles credentialing, billing, insurance contracting, and administrative tasks for affiliated clinicians, enabling therapists to focus on patient care rather than paperwork while earning more than they could through employment at a group practice. On the patient side, Alma makes it easier to find available in-network therapists — a persistent challenge in mental healthcare — through its searchable directory of affiliated providers across the country. Alma has built one of the largest networks of private practice therapists accepting insurance in the United States, with thousands of clinicians across most states. Founded in 2017, Alma raised over $220M from investors including Insight Partners, Tiger Global, and Optum Ventures. The company addresses both sides of the mental health access crisis: insufficient supply of providers and inadequate insurance reimbursement making private practice financially unviable.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.